David Mauro
Chief Tech/Sci/R&D Officer bij RECURSION PHARMACEUTICALS, INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
Momenteel bekleedt David J. Mauro de functie van Chief Medical Officer bij Prelude Therapeutics, Inc. Dr. Mauro bekleedde voorheen de positie van Chief Medical Officer & Executive Vice President bij Advaxis, Inc. en Chief Medical Officer bij Checkmate Pharmaceuticals, Inc. Dr. Mauro behaalde een doctoraal aan de Cornell University en een doctoraat aan de Temple University School of Medicine.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
09-02-2024 | 244 629 ( 0.12% ) | 2 M $ | 31-03-2024 |
Actieve functies van David Mauro
Bedrijven | Functie | Begin |
---|---|---|
RECURSION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-06-2023 |
Eerdere bekende functies van David Mauro
Bedrijven | Functie | Einde |
---|---|---|
CODIAK BIOSCIENCES | Chief Tech/Sci/R&D Officer | 07-04-2023 |
CHECKMATE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 15-10-2019 |
AYALA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-02-2016 |
MERCK & CO., INC. | Director/Board Member | 01-01-2014 |
BRISTOL-MYERS SQUIBB COMPANY | Director/Board Member | - |
Opleiding van David Mauro
Cornell University | Undergraduate Degree |
Temple University School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
MERCK & CO., INC. | Health Technology |
RECURSION PHARMACEUTICALS, INC. | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Codiak BioSciences, Inc.
Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |